Fructosamine and glycated albumin and the risk of cardiovascular outcomes and death

Elizabeth Selvin, Andreea M. Rawlings, Pamela L. Lutsey, Nisa Maruthur, James S. Pankow, Michael Steffes, Josef Coresh

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background - Hemoglobin A1c (HbA1c) is the standard measure to monitor glucose control in diabetes mellitus and is a marker of future cardiovascular risk. Fructosamine and glycated albumin are markers of short-term glycemic control, but their associations with cardiovascular outcomes are uncharacterized. Methods and Results - We measured glycated albumin and fructosamine in 11 104 participants with and without diabetes in the community-based Atherosclerosis Risk in Communities (ARIC) Study in 1990 to 1992 (baseline). We evaluated associations of fructosamine and glycated albumin with risk of coronary heart disease, ischemic stroke, heart failure, and mortality. We compared associations with those observed for HbA1c. During two decades of follow-up there were 1096 new cases of coronary heart disease, 605 of ischemic stroke, 1432 of heart failure, and 2860 deaths. Elevated baseline concentrations of fructosamine and glycated albumin were significantly associated with each of the outcomes even after adjustment for traditional cardiovascular risk factors, with especially strong associations in persons with diabetes mellitus. Associations were of similar magnitude to those observed for HbA1c and - as has been previously observed for HbA1c - the associations tended to be J-shaped, with an elevation of risk at the lowest levels of each biomarker. Conclusions - The acceptance of new measures of hyperglycemia is partly dependent on establishing their association with long-term outcomes. We found that fructosamine and glycated albumin were associated with vascular outcomes and mortality and that these associations were similar to those observed for HbA1c.

Original languageEnglish (US)
Pages (from-to)269-277
Number of pages9
JournalCirculation
Volume132
Issue number4
DOIs
StatePublished - Jul 28 2015

Fingerprint

Fructosamine
Hemoglobins
Coronary Disease
Diabetes Mellitus
Heart Failure
Stroke
Mortality
Hyperglycemia
Blood Vessels
Atherosclerosis
Biomarkers
glycosylated serum albumin
Glucose

Keywords

  • biomarkers
  • cardiovascular disease
  • diabetes mellitus
  • epidemiology
  • fructosamine
  • glycated albumin
  • hyperglycemia
  • mortality

Cite this

Fructosamine and glycated albumin and the risk of cardiovascular outcomes and death. / Selvin, Elizabeth; Rawlings, Andreea M.; Lutsey, Pamela L.; Maruthur, Nisa; Pankow, James S.; Steffes, Michael; Coresh, Josef.

In: Circulation, Vol. 132, No. 4, 28.07.2015, p. 269-277.

Research output: Contribution to journalArticle

Selvin, Elizabeth ; Rawlings, Andreea M. ; Lutsey, Pamela L. ; Maruthur, Nisa ; Pankow, James S. ; Steffes, Michael ; Coresh, Josef. / Fructosamine and glycated albumin and the risk of cardiovascular outcomes and death. In: Circulation. 2015 ; Vol. 132, No. 4. pp. 269-277.
@article{1bb2df9092ca4b689dbf4e2d3a5f78cb,
title = "Fructosamine and glycated albumin and the risk of cardiovascular outcomes and death",
abstract = "Background - Hemoglobin A1c (HbA1c) is the standard measure to monitor glucose control in diabetes mellitus and is a marker of future cardiovascular risk. Fructosamine and glycated albumin are markers of short-term glycemic control, but their associations with cardiovascular outcomes are uncharacterized. Methods and Results - We measured glycated albumin and fructosamine in 11 104 participants with and without diabetes in the community-based Atherosclerosis Risk in Communities (ARIC) Study in 1990 to 1992 (baseline). We evaluated associations of fructosamine and glycated albumin with risk of coronary heart disease, ischemic stroke, heart failure, and mortality. We compared associations with those observed for HbA1c. During two decades of follow-up there were 1096 new cases of coronary heart disease, 605 of ischemic stroke, 1432 of heart failure, and 2860 deaths. Elevated baseline concentrations of fructosamine and glycated albumin were significantly associated with each of the outcomes even after adjustment for traditional cardiovascular risk factors, with especially strong associations in persons with diabetes mellitus. Associations were of similar magnitude to those observed for HbA1c and - as has been previously observed for HbA1c - the associations tended to be J-shaped, with an elevation of risk at the lowest levels of each biomarker. Conclusions - The acceptance of new measures of hyperglycemia is partly dependent on establishing their association with long-term outcomes. We found that fructosamine and glycated albumin were associated with vascular outcomes and mortality and that these associations were similar to those observed for HbA1c.",
keywords = "biomarkers, cardiovascular disease, diabetes mellitus, epidemiology, fructosamine, glycated albumin, hyperglycemia, mortality",
author = "Elizabeth Selvin and Rawlings, {Andreea M.} and Lutsey, {Pamela L.} and Nisa Maruthur and Pankow, {James S.} and Michael Steffes and Josef Coresh",
year = "2015",
month = "7",
day = "28",
doi = "10.1161/CIRCULATIONAHA.115.015415",
language = "English (US)",
volume = "132",
pages = "269--277",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Fructosamine and glycated albumin and the risk of cardiovascular outcomes and death

AU - Selvin, Elizabeth

AU - Rawlings, Andreea M.

AU - Lutsey, Pamela L.

AU - Maruthur, Nisa

AU - Pankow, James S.

AU - Steffes, Michael

AU - Coresh, Josef

PY - 2015/7/28

Y1 - 2015/7/28

N2 - Background - Hemoglobin A1c (HbA1c) is the standard measure to monitor glucose control in diabetes mellitus and is a marker of future cardiovascular risk. Fructosamine and glycated albumin are markers of short-term glycemic control, but their associations with cardiovascular outcomes are uncharacterized. Methods and Results - We measured glycated albumin and fructosamine in 11 104 participants with and without diabetes in the community-based Atherosclerosis Risk in Communities (ARIC) Study in 1990 to 1992 (baseline). We evaluated associations of fructosamine and glycated albumin with risk of coronary heart disease, ischemic stroke, heart failure, and mortality. We compared associations with those observed for HbA1c. During two decades of follow-up there were 1096 new cases of coronary heart disease, 605 of ischemic stroke, 1432 of heart failure, and 2860 deaths. Elevated baseline concentrations of fructosamine and glycated albumin were significantly associated with each of the outcomes even after adjustment for traditional cardiovascular risk factors, with especially strong associations in persons with diabetes mellitus. Associations were of similar magnitude to those observed for HbA1c and - as has been previously observed for HbA1c - the associations tended to be J-shaped, with an elevation of risk at the lowest levels of each biomarker. Conclusions - The acceptance of new measures of hyperglycemia is partly dependent on establishing their association with long-term outcomes. We found that fructosamine and glycated albumin were associated with vascular outcomes and mortality and that these associations were similar to those observed for HbA1c.

AB - Background - Hemoglobin A1c (HbA1c) is the standard measure to monitor glucose control in diabetes mellitus and is a marker of future cardiovascular risk. Fructosamine and glycated albumin are markers of short-term glycemic control, but their associations with cardiovascular outcomes are uncharacterized. Methods and Results - We measured glycated albumin and fructosamine in 11 104 participants with and without diabetes in the community-based Atherosclerosis Risk in Communities (ARIC) Study in 1990 to 1992 (baseline). We evaluated associations of fructosamine and glycated albumin with risk of coronary heart disease, ischemic stroke, heart failure, and mortality. We compared associations with those observed for HbA1c. During two decades of follow-up there were 1096 new cases of coronary heart disease, 605 of ischemic stroke, 1432 of heart failure, and 2860 deaths. Elevated baseline concentrations of fructosamine and glycated albumin were significantly associated with each of the outcomes even after adjustment for traditional cardiovascular risk factors, with especially strong associations in persons with diabetes mellitus. Associations were of similar magnitude to those observed for HbA1c and - as has been previously observed for HbA1c - the associations tended to be J-shaped, with an elevation of risk at the lowest levels of each biomarker. Conclusions - The acceptance of new measures of hyperglycemia is partly dependent on establishing their association with long-term outcomes. We found that fructosamine and glycated albumin were associated with vascular outcomes and mortality and that these associations were similar to those observed for HbA1c.

KW - biomarkers

KW - cardiovascular disease

KW - diabetes mellitus

KW - epidemiology

KW - fructosamine

KW - glycated albumin

KW - hyperglycemia

KW - mortality

UR - http://www.scopus.com/inward/record.url?scp=84938566751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938566751&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.115.015415

DO - 10.1161/CIRCULATIONAHA.115.015415

M3 - Article

C2 - 26022911

AN - SCOPUS:84938566751

VL - 132

SP - 269

EP - 277

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 4

ER -